In this issue of CSO series, we focus on the contributions of Dr Kalyanasundaram Subramanian, CSO, Strand Life Sciences
, and Dr Shireen Vali, CSO, CellWorks
, towards development of technology-based solutions to enable drug discovery R&D, improve productivity and success rate of the process, reduce costs, increase efficiency, and identify potential side-effects.
The business objective of any BioIT company is to support the pharma companies, which are under tremendous pressure due to rising R&D costs, drying of product pipeline and regulatory hurdles. Companies, such as Strand Life Sciences and CellWorks, have been working towards meeting this aim.